Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of oral octreotide capsules versus injectable somatostatin receptor ligands in controlled acromegaly
NL-OMON43570Phase 3Withdrawn
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide, lanreotide and cabergoline in acromegaly (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Biochemical control throughout the randomized controlled phase. Planned start Mar 2016; status: withdrawn.
02
Drugs
octreotidelanreotidecabergoline
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON43570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43570.